La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ANGLE Salute del bilancio

Salute finanziaria criteri di controllo 6/6

ANGLE ha un patrimonio netto totale di £22.9M e un debito totale di £0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente £31.2M e £8.2M.

Informazioni chiave

Rapporto debito/patrimonio netto

UK£0

Debito

Indice di copertura degli interessi	n/a
Contanti	UK£16.22m
Patrimonio netto	UK£22.94m
Totale passività	UK£8.24m
Totale attività	UK£31.18m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Mar 20

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

Dec 02

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Aug 11

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Feb 28

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Jul 16

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Aug 23

We're Not Very Worried About ANGLE's (LON:AGL) Cash Burn Rate

May 02

What Type Of Shareholders Make Up ANGLE plc's (LON:AGL) Share Registry?

Feb 14

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Dec 22

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( £21.2M ) di AGL superano le sue passività a breve termine ( £3.9M ).

Passività a lungo termine: Le attività a breve termine di AGL ( £21.2M ) superano le sue passività a lungo termine ( £4.3M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: AGL è esente da debiti.

Riduzione del debito: AGL non aveva debiti 5 anni fa.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: AGL ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: Si prevede che AGL disponga di liquidità sufficiente per 11 mesi in base alle stime del flusso di cassa libero, ma da allora ha raccolto capitale aggiuntivo.

ANGLE Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Recent updates

Angle plc Announces the Publication of One of the Company's Clinical Studies That Was Submitted to the FDA for De Novo Regulatory Clearance of the Parsortix PC1 System

New minor risk - Shareholder dilution

Full year 2023 earnings released: UK£0.077 loss per share (vs UK£0.088 loss in FY 2022)

ANGLE plc Provides Revenue Guidance for the First Half of 2024

ANGLE plc to Report Q4, 2023 Results on Jun 07, 2024

ANGLE plc Announces Publication of Study Using the Parsortix System

ANGLE plc, Annual General Meeting, Jun 26, 2024

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Consensus revenue estimates decrease by 17%

Consensus revenue estimates decrease by 17%

Price target increased by 15% to UK£1.09

Angle plc Announces Use of Parsortix System in Pre-Clinical Model Unlocks Opportunities for Drug Discovery

ANGLE plc Launches Portrait+ CTC Kit At SABCS

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Announces the Launch of Its Portrait® PD-L1 Test for the Evaluation of PD-L1 Protein Expression on CTCs Following Extensive Development and Optimisation

First half 2023 earnings released: UK£0.038 loss per share (vs UK£0.039 loss in 1H 2022)

Angle plc Announces the Launch of Its Portrait™ Flex Ctc Assay

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

Price target decreased by 35% to UK£0.94

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

Insufficient new directors

ANGLE plc to Report Fiscal Year 2022 Results on Jun 02, 2023

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

ANGLE plc Announces the Publication of Results from A Multi-Centre Clinical Study

Angle plc Announces It Presented Results from A Proof of Concept Study At the International Society of Liquid Biopsy Meeting in Miami, Florida

ANGLE plc Announces Streamlining of Operations to Increase Cash Runway

First half 2022 earnings: EPS and revenues miss analyst expectations

ANGLE plc Announces Positive Headline Results from Ovarian Study

ANGLE plc Announces Study Using Parsortix in Head and Neck Cancer

ANGLE plc Announces the Publication of Results from A Clinical Study Undertaken in Partnership with the Wilmot Cancer Institute, University of Rochester, NY, US

Price target increased to UK£2.16

Angle plc Announces New Study Highlights Use of Parsortix System to Enable Cancer Cell Dna Analysis in Non-Small Cell Lung Cancer

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

ANGLE plc Announces Ground-Breaking Research by the World-Class Team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology Zurich, Switzerland

Angle plc Announces Results of Work Undertaken in Advanced Non-Small Cell Lung Cancer (NSCLC) and Sarcoma Patients

Angle plc Receives FDA Clearance for Parsortix

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target increased to UK£1.85

Insufficient new directors

ANGLE plc, Annual General Meeting, Jun 29, 2022

ANGLE plc to Report Fiscal Year 2021 Results on Apr 28, 2022

Angle Announces Parsortix System Shows Potential for Providing Rapid Information on Patient Response to Therapies Targeting Metastasis

ANGLE plc Announces the Edith Cowan University, Perth, Australia, Has Published Results from A Study in Ovarian Cancer Patients Using the Parsortix® System

Price target increased to UK£1.80

ANGLE plc Announces the Publication of Research Undertaken by the World-Class Team At the University of Southern California Norris Cancer Center

ANGLE plc Provides Update on Lab Accreditation and Ovarian Study

Insufficient new directors

First half 2021 earnings released: UK£0.036 loss per share (vs UK£0.02 loss in 1H 2020)

ANGLE plc Announces Parsortix System Demonstrates Ability to Isolate CTCS for Downstream Gene Analysis Revealing Multiple Prognostic Biomarkers

Angle plc Announces That the Health Research Institute of Santiago

CFO, Finance Director exercised options to buy UK£524k worth of stock.

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Founder exercised options and sold UK£1.0m worth of stock

Forecast to breakeven in 2025

ANGLE plc Announces Published Results of A New Study Undertaken in Non-Small Cell Lung Cancer

Angle plc Announces Breakthrough Research Supports Potential Use of Parsortix in Prevention of Relapse of Breast Cancer Patients in Remission

Angle's Parsortix System Harvests Intact CTCs for Whole Genomic Sequencing Identifying Multiple Druggable Targets

We're Not Very Worried About ANGLE's (LON:AGL) Cash Burn Rate

Full year 2020 earnings released: UK£0.065 loss per share (vs UK£0.057 loss in FY 2019)

ANGLE plc Announces Patient Enrolment Completed in Ovarian Cancer Clinical Verification Study

Angle plc Provides Update on Submission for FDA Clearance of the Parsortix System

What Type Of Shareholders Make Up ANGLE plc's (LON:AGL) Share Registry?